# NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct07224152/  
OnCo record `nct07224152` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JNJ-90301900 in lung cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07224152 by M.D. Anderson Cancer Center, with a registry enrolment figure of 40 participants, started 2026-03-27 and due to reach its primary completion in 2028-08-30. Interventions recorded: NBTXR3. Conditions listed: Locally-Advanced Non-Small Cell Lung Cancer. Primary outcome: Safety and Adverse Events (AEs). Lung eligibility wording from the registry: "Biopsy proven stage I-III NSCLC". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07224152
- Phase: 1/2
- Setting: NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07224152: https://clinicaltrials.gov/study/NCT07224152

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [JNJ-90301900](https://onco.cc/drugs/jnj-90301900/)
- companies: [Nanobiotix](https://onco.cc/companies/nanobiotix/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07224152.json